Topic: Acute Myeloid Leukemia.
Destination: Aid through which Pfizer will finance programs for the training of health professionals on advances in the treatment of Acute Myeloid Leukemia (AML) in patients not suitable for intensive chemotherapy, with the aim of helping these professionals in making decisions for evidence-based treatment.
Budget: 15 months.
Duration: $150,000.
Fill out the form below to receive more information: